Primary Cells Market Report 2026

The primary cells market size has grown rapidly in recent years. It will grow from $1.67 billion in 2025 to $1.84 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to expansion of biomedical research activities, increased use of cell-based disease models, rising investment in cancer research, growth of virology and immunology studies, availability of advanced cell isolation techniques.

The primary cells market size is expected to see strong growth in the next few years. It will grow to $2.68 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing demand for precision medicine applications, rising adoption of primary cells in drug discovery, expansion of regenerative medicine research, growing use of ai-driven cell analytics, increasing investment in advanced cell therapies. Major trends in the forecast period include increasing use of primary cells in translational research, growing adoption of 3D cell culture models, rising demand for human-derived primary cells, expansion of personalized cell-based assays, enhanced focus on cell quality and traceability.

The rising incidence of cancer is expected to drive the growth of the primary cells market in the coming years. Cancer is a condition in which certain cells in the body multiply uncontrollably, spread to other areas, and interfere with normal bodily functions. Cancer cases are increasing as longer life expectancy results in more individuals reaching ages at which cancer naturally occurs more frequently, thereby raising overall incidence rates. Primary cells support cancer research by offering biologically relevant cell models that enable researchers to examine tumor behavior and evaluate potential therapies with greater reliability. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international health organization, more than 35 million new cancer cases are projected by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. In terms of absolute burden, countries with a high Human Development Index are expected to see the largest increase, with an additional 4.8 million new cases anticipated in 2050 compared with 2022 estimates. Therefore, the increasing number of cancer cases is expected to propel the growth of the primary cells market.

Major companies operating in the primary cells market are concentrating on advancements in cell-based products, including cell culture and stem cell solutions, to strengthen research applications and therapeutic development. A novel serum-free medium is a culture or growth medium used in cell or tissue culture that does not include serum, particularly fetal bovine serum (FBS) or other animal-derived sera. For instance, in July 2024, Bioserve Biotechnologies (India) Private Ltd., an India-based provider of biotechnology and life sciences solutions, introduced advanced stem cell products in India. These newly launched products from REPROCELL are designed to support innovation in scientific research and drug development, contributing to progress in regenerative medicine and therapeutic discovery within the Indian region.

In April 2023, AnaBios Corporation, a US-based biotechnology company, acquired Cell Systems for an undisclosed amount. This acquisition was intended to broaden AnaBios’ portfolio of human tissue and cell offerings, deliver improved translational tools and reagents to academic, pharmaceutical, and biotechnology researchers, and enhance research programs through deeper human-based insights. Cell Systems is a US-based biotechnology company specializing in the supply of human primary cells and cell culture media.

Major companies operating in the primary cells market are Thermo Fisher Scientific Inc, Merck KGaA, BD Biosciences, Corning Incorporated, Cytiva, Lonza Group Ltd, Charles River Laboratories Inc, STEMCELL Technologies Inc, American Type Culture Collection, BioIVT, InvivoGen, HemaCare Corporation, Creative Bioarray Inc, PromoCell GmbH, CellGenix, AllCells LLC, Axol Bioscience Ltd, AnaBios Corporation, ReachBio Research Labs, PELOBIOTECH GmbH, Cell Biologics Inc, ZenBio Inc, StemBioSys Inc, MatTek Corporation.

North America was the largest region in the primary cells market in 2025. The regions covered in the primary cells market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the primary cells market by increasing costs of imported laboratory reagents, culture media, cryopreservation equipment, and analytical instruments essential for primary cell isolation and maintenance. Research institutions and biopharmaceutical companies in North America and Europe are most affected due to dependence on specialized imported consumables, while Asia-Pacific faces higher costs in exporting cell-based research materials. These tariffs are increasing research expenses and extending procurement timelines. However, they are also encouraging local production of laboratory reagents, regional cell banking initiatives, and domestic investment in advanced life science research infrastructure.

The primary cells market research report is one of a series of new reports that provides primary cells market statistics, including primary cells industry global market size, regional shares, competitors with a primary cells market share, detailed primary cells market segments, market trends and opportunities, and any further data you may need to thrive in the primary cells industry. This primary cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Primary cells are cells isolated directly from the living tissues of humans or animals and subsequently processed for use in appropriate cell-based applications. These cells are used across a wide range of applications, including 3D cell culture, virology, cancer research, stem cell therapy, and tissue regeneration.

The primary categories of primary cells include hematopoietic cells, dermatophytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and others. Hematopoietic cells are a type of stem cell responsible for generating the different types of blood cells in the body. These cells are derived from human primary cells and animal primary cells, and their end users include pharmaceutical companies, biotechnology companies, contract research organizations (CROs), academic institutions, and research institutes, among others.

The primary cells market consists of revenues earned by entities by providing services such as cell isolation services, primary cell culture services, cell characterization, and authentication. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary cell market also includes sales of cell culture media and reagents, cell culture plates and flasks, cell isolation kits, and transfection reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.